Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Karyopharm Therapeutics Inc

+ Add to Watchlist

KPTI:US

28.3200 USD 0.2800 0.98%

As of 20:10:00 ET on 01/27/2015.

Snapshot for Karyopharm Therapeutics Inc (KPTI)

Open: 28.9300 Day's Range: 27.9100 - 29.1200 Volume: 162,020
Previous Close: 28.6000 52wk Range: 23.8650 - 49.0050 1-Yr Rtn: -5.57%

Stock Chart for KPTI

No chart data available.
  • KPTI:US 28.2700
  • 1D
  • 1M
  • 1Y
28.6000
Interactive KPTI Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KPTI

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -3.1349
Est. EPS (USD) (12/2014) -2.2170
Est. PEG Ratio -
Market Cap (M USD) 1,009.39
Shares Outstanding (M) 35.64
30 Day Average Volume 502,542
Price/Book (mrq) 4.0545
Price/Sale (ttm) 2,905.2401
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KPTI

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for KPTI

Karyopharm Therapeutics, Inc. provides biopharmaceutical products and services. The Company develops and discovers drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation through activity modulation of critical pathways. Karyopham Therapeutics serves the healthcare industry throughout the United States.

Michael G KauffmanCEO/Co-FounderSharon ShachamPresident/Chief Scientific Ofcr
Justin A RenzExec VP/CFOChristopher B PrimianoVP/Secretary/General Counsel
More Company Profile & Key Executives for KPTI

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil